Aim: Pirarubicin (THP) is recently found to be effective in treating patients with advanced, relapsed or recurrent high-grade osteosarcoma. In this study, the effects of THP on the multidrug-resistant (MDR) osteosarcoma cells were assessed, and the underlying mechanisms for the disruption of cell cycle kinetics by THP were explored. Methods: Human osteosarcoma cell line MG63 and human MDR osteosarcoma cell line MG63/DOX were tested. The cytotoxicity of drugs was examined using a cell proliferation assay with the Cell Counting Kit-8 (CCK-8). The distribution of cells across the cell cycle was determined with flow cytometry. The expression of cell cycle-regulated genes cyclin B1 and Cdc2 (CDK1), and the phosphorylated Cdc2 and Cdc25C was examined using Western blot analyses. Results: MG63/DOX cells were highly resistant to doxorubicin (ADM) and gemcitabine (GEM), but were sensitive or lowly resistant to THP, methotrexate (MTX) and cisplatin (DDP). Treatment of MG63/DOX cells with THP (200-1000 ng/mL) inhibited the cell proliferation in time-and concentration-dependent manners. THP (50-500 ng/mL) induced MG63/DOX cell cycle arrest at the G 2 /M phase in time-and concentration-dependent manners. Furthermore, the treatment of MG63/DOX cells with THP (200-1000 ng/mL) downregulated cyclin B1 expression, and decreased the phosphorylated Cdc2 at Thr
Introduction
Osteosarcoma is the most common malignant primary bone tumor in children, adolescents and young adults. Multiagent chemotherapy, commonly including doxorubicin (ADM), cisplatin (DDP) and high-dose methotrexate (MTX), has improved patient survival from 11% with surgical resection alone to 70% for localized disease. Unfortunately, the longterm survival for the remaining patients with recurrent disease is less than 20% [1] [2] [3] . Studies designed to identify novel active agents and implement strategies to overcome chemoresistance will likely be important for improving survival [1] .
Recently, pirarubicin (THP), a novel anthracycline derivative of ADM, has been used clinically to treat tumors such as osteosarcoma, breast cancer, lymphoma and acute myeloid leukemia [4] [5] [6] [7] . Moreover, THP has shown a greater antitumor activity [8] [9] [10] and lower cardiotoxicity [11] than ADM. This may be explained by the higher uptake of THP by tumor cells than ADM and its rapid distribution into the nucleus and subsequent incorporation into deoxyribonucleic acid (DNA) [12] [13] [14] . More recently, we found that through retrospective analysis, THP-based chemotherapy regimens were effective and safe as a salvage chemotherapy option for patients with lung metastases, refractory or recurrent high-grade osteosarcoma who previously received adjuvant chemotherapy with high dose-MTX-DDP-ADM-ifosfamide [15, 16] . However, the exact mechanisms by which THP exerts its antitumor effects are not understood. Although previous studies on THP www.chinaphar.com Zheng SE et al Acta Pharmacologica Sinica npg have revealed that induction of cell cycle arrest at the G 2 phase may contribute to its action in RPMI-8402 cells [17] , the molecular basis of the cell cycle arrest induced by THP remains unclear.
Considering this previous research, we speculated that THP might be a potential chemotherapeutic agent that can circumvent drug resistance in patients with osteosarcoma. However, few studies clearly define the effects of THP on cytotoxicity and multidrug-resistant (MDR) osteosarcoma cells. In this study, we investigated the in vitro cytotoxic response of the MDR osteosarcoma cell line MG63/DOX treated with THP and explored the underlying mechanisms THP utilizes to disrupt cell cycle kinetics.
Materials and methods
Reagents THP was obtained from Wan Le Pharma (Shenzhen, China); ADM and MTX, from Pfizer Pharma (New York, NY, USA); gemcitabine (GEM), from Lilly Pharma (Saint-Cloud, France); and DDP, from Hao Shen Pharma (Nanjing, China). Propidium iodide (PI) was purchased from Sigma Chemicals (St Louis, MO, USA). Cell Counting Kit-8 (CCK-8) was purchased from Dojindo Laboratories (Kumamoto, Japan).
Cell lines and cell culture
The human osteosarcoma parental cell line, MG63, was obtained from the Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences (Shanghai, China). The human MDR osteosarcoma cell line MG63/DOX, which overexpresses P-glycoprotein (P-gp) and was selected in a step-wise manner by exposing drug-sensitive MG63 cells to increasing doses of ADM, was kindly provided by Dr Yoshio ODA (Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan) [18] . The cells were cultured in Dulbecco's modified Eagle's medium (DMEM; Hyclone, Logan, UT, USA) supplemented with 10% heat-inactivated fetal calf serum (FCS; Si Ji Qing, Hangzhou, China), 100 units/mL penicillin and 100 mg/mL streptomycin (Gibco, Grand Island, NY, USA) in a humidified atmosphere at 37 °C consisting of 5% CO 2 . Drugs were initially dissolved in phosphate-buffered saline (PBS) and then serially diluted in culture medium to the desired drug treatment concentrations.
Drug sensitivity and cytotoxicity assays
The effects of THP, ADM, MTX, DDP, and GEM on the proliferation of MG63/DOX and MG63 cells were measured using the CCK-8 colorimetric assay. Briefly, the cells were seeded in a 96-well microtiter plate at 5×10 3 cells/well (100 μL). After 24 h of incubation with fresh medium, 10 μL of the various chemical dilutions at the indicated concentrations of each drug was added to the plates, and the cells were incubated for an additional 24, 48, and 72 h. At the end of drug treatment, 10 μL of CCK-8 was added to each well, and the cells were incubated for 4 h at 37 °C. Absorbance (A) was analyzed on a 96-well Opsys MR Microplate Reader (Thermo Labsystems, Beverly, MA, USA) at 450 nm. All experiments were tested in triplicate and repeated at least three times. The resistance factor (R factor) of multidrug-resistant cell line MG63/DOX for a particular drug is defined as the ratio of IC 50 of MG63/DOX cell to IC 50 of MG63 cell at 72 h (R<5×: low or no-resistance; R 5-15×: moderate-resistance; R>20×: high-resistance) [19] .
Cell cycle analysis MG63/DOX cells were treated with THP for 24, 48, and 72 h at concentrations of 50, 200, and 500 ng/mL. Control cells were treated with solvent alone for the durations indicated above. Cell cycle was analyzed as previously described [20] . The cells were trypsinized, washed twice with ice cold PBS, fixed in 70% ethanol and stained with propidium iodide (PI; 5 μg/mL PI in PBS containing 0.1% Triton X-100 and 0.2 mg/mL RNase A) in the dark for 30 min at 4 °C. Finally, the cells were analyzed for cell cycle perturbation using a FACSCalibur flow cytometer (Becton-Dickinson, San Diego, CA, USA). Cell fluorescence was measured in duplicate at each time point, and all experiments were performed in triplicate.
Western blot analysis
Cells treated with THP at the indicated concentrations were harvested following 72 h of incubation. Western blotting was performed as described previously [21] . Briefly, 30 μg of protein from whole-cell lysates was separated on a sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) apparatus and electrotransferred onto polyvinylidene fluoride (PVDF) membranes (Millipore, Bedford, MA, USA). After blocking with 5% (w/v), non-fat dry milk in Trisbuffered saline for 1 h at room temperature, membranes were incubated overnight at 4 °C with the previously described pretreated antibody diluent according to the one-step Western kit manufacturer's instructions. Primary antibodies were incubated with a horseradish peroxidase antibody for 5 min at room temperature and then diluted (1:1000). The protein bands were visualized using a chemiluminescence imaging system (Bio-Rad, Hercules, CA, USA). All blots are representative of three independent experiments. Primary antibodies assayed were Cyclin B1, Cdc2, p-Cdc2 (Thr  14 ) , p-Cdc2 (Tyr 15 ), and p-Cdc2 (Thr 161 ) antibodies (Cell Signaling Technology, Boston, MA, USA); Cdc25C and p-Cdc25C (Ser 216 ) antibodies (Santa Cruz Biotechnology, Inc, Santa Cruz, CA, USA); and β-actin antibody (CoWin Biotech Co, Beijing, China).
Statistical analysis
Data are presented as the mean±SD. The Student's t-test was used to analyze the difference between the mean values of the treatment and the control groups. Differences with a P value of less than 0.05 were considered statistically significant.
Results

Drug sensitivity
We investigated the effects of THP and chemotherapeutic agents commonly used for osteosarcoma treatment, including ADM, MTX, DDP, and GEM, on the proliferation of MG63/ DOX MDR human osteosarcoma cells and their parental [18] . Surprisingly, THP had similar inhibitory effects on cell proliferation in both resistant and parental osteosarcoma cells, indicating that MDR osteosarcoma cells are still sensitive to THP.
THP inhibited proliferation of MG63/DOX cells
The cytotoxic effects of THP on MG63/DOX cells were further measured with the CCK-8 colorimetric assay after the cells were exposed to various concentrations of THP for multiple durations. Cell growth was inhibited in a concentration-and time-dependent manner ( Figure 1 and Table 2 ).
THP induced MG63/DOX cells cycle arrest at the G 2 /M phase To examine the mechanism of inhibition of cell growth by THP, cell cycle perturbation was evaluated by flow cytometry after the MG63/DOX cells were exposed to THP at various concentrations for 24, 48, or 72 h. As shown in Figure 2 and Table 3 THP reduced cyclin B1 expression and Cdc2 and Cdc25C activity To elucidate the molecular basis for THP-induced cell cycle arrest at the G 2 /M phase, Cyclin B1, and Cdc2 protein expression was assayed by Western blotting. As shown in Figure 3 , the results indicate that protein levels of cyclin B1 decreased after THP treatment in a time-and concentration-dependent manner but that the total protein levels of Cdc2 did not The resistance factor (R factor) of multidrug-resistant cell line MG63/DOX for a particular drug is defined as the ratio of IC 50 of MG63/DOX cell to IC 50 of MG63 cell at 72 h. R factor<5: low or no-resistance; R factor 5-15: moderate-resistance; R factor >20: high-resistance [19] . (Figure 3) . These results suggest that decreased dephosphorylation by Cdc25C is partly responsible for Cdc2 inactivation.
Discussion
Currently, one of the greatest obstacles to improving the survival of patients with osteosarcoma is acquired clinical resistance to chemotherapeutic agents, primarily to the three most widely used agents in the treatment of osteosarcoma -ADM, MTX, and DDP [1, 22, 23] . Cancer cells can utilize a number of different mechanisms to become resistant to one or more chemotherapeutic drugs. Depending on the drug and cellular context, factors such as drug inactivation, drug target mutation, drug target upregulation and downregulation, decreased drug uptake, increased drug elimination and DNA damage repair have all been shown to contribute to both intrinsic and acquired resistant to chemotherapy [1] . ADM is one of the most effective agents for osteosarcoma treatment [1, 22, 23] . Although resistance to ADM in osteosarcoma is likely to be multifactorial, P-gp is thought to be the main resistance mechanism against this agent [1, 24] . Additionally, some retrospective studies [25, 26] have revealed that the overexpression of P-gp may be associated with poor prognosis. THP, a semisynthetic anthracycline glycoside, is a newer generation anthracycline anticancer agent that is reported to have a lower cardiotoxicity than ADM [11] . Changes in structure allow THP to be taken up by tumor cells approximately 170 times faster than ADM and increase the rates at which it distributes into the nucleus and Table 3 ). A representative profile is shown for each treatment.
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Acta Pharmacologica Sinica npg intercalates into DNA [12] [13] [14] . On the basis of these considerations, we tested THP for cytotoxicity against MDR osteosarcoma MG63/DOX cells in vitro. We found that THP has a marked inhibitory effect on cell proliferation in both resistant and sensitive osteosarcoma cells. These results suggest that THP partially overcomes the resistance caused by overexpression of P-gp and that THP may play an important role in treatment of patients with refractory or recurrent high-grade osteosarcoma. In fact, THP has also shown favorable activity in various types of cancer cells, including P-gp overexpressing breast cancer [27] , ADM-resistant lymphoblastoma [28] , MG-63 cells [29] and bladder cancers [30] in vitro, and has substantial clinical activity against various tumors without severe side effects [4] [5] [6] [7] 15, 16] . Despite the ability of THP to overcome MDR in clinical studies [6, 16, 17] , very little is known about THP-induced cytotoxicity and the underlying mechanisms of pirarubicin on MDR osteosarcoma cells. To our knowledge, this is the first study to evaluate the cytotoxicity of THP against human drug-resistant osteosarcoma cells.
In addition, we demonstrated that the effect of THP in resistant MG63/DOX cells is associated with cell cycle arrest at the G 2 /M phase in a time-and concentration-dependent manner. Similarly, Takamoto et al [17] reported that THP exerted its growth-inhibitory effect by blocking RPMI-8402 cells irreversibly at G 2 and that the G 2 phase accumulation was a cytocidal effect of THP. The eukaryotic cell cycle is strictly regulated by a class of cyclins and cyclindependent kinases (CDKs) [31] . The progression from G 2 to mitosis is controlled by the mitosispromoting factor, which comprises a complex of Cdc2 (CDK1) and cyclin B [32] [33] [34] [35] . During G 2 /M transition, CDK1 activation requires an association with cyclin B1 and phosphorylation at Thr 161 by CDK-activating kinase (CAK), whereas the CDK1/ cyclin B complex is kept inactive by phosphorylation on Thr 14 or Tyr 15 of CDK1 by kinase Wee1 and Myt1 [36] . We found that THP significantly downregulated cyclin B1, p-Cdc2 ( [37] . It is proposed that the checkpoint kinase, Chk1, regulates the interactions between human Cdc25C and 14-3-3 proteins by phosphorylating Cdc25C on serine 216. 14-3-3 proteins, in turn, function to keep Cdc25C out of the nucleus [38] . Therefore, the effect of THP on G 2 /M phase arrest in MG63/DOX cells may be partly mediated by Chk1 activation. However, future studies are required to determine whether and how THP affects Chk1 in our model system.
In conclusion, we have demonstrated an encouraging efficacy of THP against human MDR osteosarcoma cells in vitro. We also have found, for the first time, that THP could arrest the cell cycle at the G 2 /M phase, which was partially associated with the downregulation of cyclin B1, p-Cdc2 (Thr 161 ), and the upregulation of p-Cdc2 (Thr  14 ) , p-Cdc2 (Tyr  15 ) , and p-Cdc25C (Ser 216 ). The alterations of cell cycle kinetics might contribute to a better understanding of the cytotoxicity induced by THP. These findings also provide a theoretical basis for its potential use in the management of patients with MDR osteosarcoma and suggest that further in vivo and prospective clinical studies are warranted.
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